Integral Molecular

51 articles with Integral Molecular

• Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors

  11/29/2022

  Context Therapeutics Inc. today announced the selection of CTIM-76, a T cell-engaging bispecific antibody, as its lead clinical development candidate to target Claudin 6 (CLDN6) positive cancers, resulting from its research collaboration and licensing agreement with Integral Molecular.

• Integral Molecular Licenses Claudin 18.2 Monoclonal Antibodies to CARTEXELL for Oncology Cell Therapies

  9/15/2022

  Integral Molecular, the industry leader in discovering antibodies against complex membrane protein targets, has licensed a panel of monoclonal antibodies (MAbs) to CARTEXELL, enabling CARTEXELL to develop CAR-T cell therapies using Integral Molecular's Claudin 18.2 (CLDN18.2) MAbs.

• Integral Molecular Enters into Antibody License Agreement with AstraZeneca for Oncology Therapeutics

  11/3/2021

  Integral Molecular, an industry leader in developing antibodies against membrane proteins, announced that it entered into an exclusive worldwide antibody license agreement with AstraZeneca to develop therapeutics for multiple cancers.

• Integral Molecular and Integrated BioTherapeutics Collaborate to Engineer Broadly Protective Ebolavirus Vaccines

  11/2/2021

  A collaboration between Integral Molecular and Integrated BioTherapeutics, two biotechnology companies with deep expertise in virology, has resulted in engineered proteins that may enable next-generation vaccines with broad protection against Ebola and related viruses.

• Philadelphia Biotech Integral Molecular Celebrates 20 Years of Innovation, Growth, and Community

  10/12/2021

  Integral Molecular, a founding member of Philadelphia's biotech community, celebrates its 20th anniversary as a leader in antibody discovery and virology.

• Integral Molecular Launches Transgene Protein Engineering Platform to Address Challenges in Gene Therapy

  7/30/2021

  Integral Molecular, the industry leader in membrane proteins, announces the launch of GeneCanvas, its proprietary protein engineering platform to optimize transgenes and other gene therapy elements.

• 

  Top 10 Pharm Country Companies to Receive NIH Funding in 2020

  3/3/2021

  Across the Pharm Country Hotbed, the agency has provided hundreds of millions of dollars to universities, research institutes and pharmaceutical companies.

• Totient Leverages Integral Molecular's Membrane Proteome Array to Advance Cancer Therapeutic Discovery

  10/14/2020

   Integral Molecular and Totient announce a partnership leveraging Integral Molecular's Membrane Proteome Array (MPA) target identification technology to advance the discovery of antibodies for cancer therapy. Totient reconstructs antibodies from tertiary lymphoid structures (TLS), which are structures formed in tissues affected by aut

• Integral Molecular Awarded Grant from the Commonwealth of Pennsylvania to Advance COVID-19 Research

  9/21/2020

  Integral Molecular has been awarded $521,723 from the Commonwealth of Pennsylvania to leverage its technologies in the global fight against COVID-19.

• Integral Molecular Expands its Reporter Virus Technology to Enable Broad Testing for Coronavirus Protection Against Emerging Strains Including D614G

  7/14/2020

  Integral Molecular has launched an expanded panel of SARS-CoV-2 Reporter Virus Particles (RVP), which includes spike protein variants such as D614G and spike protein from other related coronaviruses.

• Integral Molecular Provides Rapid Safety Testing of COVID-19 Antibody Therapeutics with its Membrane Proteome Array Technology

  6/12/2020

  Integral Molecular, the leader in discovering and characterizing antibodies against membrane protein and viral targets, is applying its Membrane Proteome Array (MPA) technology for antibody specificity profiling to promote the rapid development of SARS-CoV-2 therapeutic antibodies.

• Integral Molecular Accelerates Coronavirus Vaccine Research

  3/9/2020

  Integral Molecular announces the mobilization of two of its key technology platforms to aid in the discovery of vaccines and therapeutics against the novel coronavirus which causes COVID-19.

• Integral Molecular Announces Preclinical P2X7 Antibody Assets for Autoimmune Disorders

  1/9/2020

  Integral Molecular, the leader in discovering antibodies against multipass membrane proteins, announces lead monoclonal antibodies (MAbs) against P2X7, a structurally complex ion channel that is the target for autoimmune disorders including atopic dermatitis and glomerulonephritis.

• 

  Antibody Discovery Platform, Partnerships Help Fuel Integral Molecular's Growth

  11/22/2019

  The company has doubled its headcount to about 60 employees and doubled its square-footage in the city with the 26,000 square-foot facility.

• Philadelphia's Integral Molecular Opens New Research Center in Response to Upsurge in Antibody Discovery Partnerships

  10/18/2019

  Integral Molecular, the industry leader in membrane protein solutions, has expanded its research facility to a second location to accommodate an upsurge in MPS Antibody Discovery partnerships and the progression of its internal therapeutic antibody pipeline

• Integral Molecular Selected as the First Industry Partner in The Wistar Institute's Biomedical Research Technician Apprenticeship

  9/26/2019

  Integral Molecular, Inc. has been selected by The Wistar Institute, a global leader in cancer, immunology and infectious disease research as the first industry partner for its Biomedical Research Technician Apprenticeship.

• Integral Molecular Presents Data on Monoclonal Antibodies (MAbs) Against SLC2A4 (GLUT4), a Critical Target for Diabetes

  6/26/2019

  These rare antibodies were discovered using Integral Molecular's MPS Antibody Discovery platform.

• Integral Molecular Reaches Milestone in Immuno-Oncology Target Discovery Collaboration with Daiichi Sankyo

  5/28/2019

  Integral Molecular, the industry leader in discovering antibodies against multipass membrane proteins, today announced that it has successfully reached the first milestone in its collaboration with Daiichi Sankyo Co., Ltd.

• Integral Molecular Doubles Antibody Characterization Capacity Within Philadelphia's Science Center

  4/16/2019

  Integral Molecular announced the expansion of its two proprietary antibody characterization platforms, Shotgun Mutagenesis Epitope Mapping and the Membrane Proteome Array.

• Integral Molecular Enters Immuno-Oncology Target Discovery Collaboration with Daiichi Sankyo

  1/7/2019

  Specific financial terms of the agreement have not been disclosed.